Gene delivery and gene expression in vertebrate using baculovirus <i>Bombyx mori</i> nucleopolyhedrovirus vector

Xingjian Liu, Yinü Li, Xiaoyuan Hu, Yongzhu Yi, Zhifang Zhang

Oncotarget · 2017 · 18 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

// Xingjian Liu 1, * , Yin&uuml; Li 1,* , Xiaoyuan Hu 1 , Yongzhu Yi 2 and Zhifang Zhang 1 1 Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing, China 2 The Sericultural Research Institute, Chinese Academy of Agricultural Sciences, Zhenjiang, China * These authors have contributed equally to this work Correspondence to: Zhifang Zhang, email: zhifangzhang@yahoo.com Keywords: Bombyx mori nucleopolyhedrovirus; complement resistance; gene delivery Received: July 06, 2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accepted: October 28, 2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Published: November 20, 2017 ABSTRACT The baculovirus Autographa californica multicapsid nucleopolyhedrovirus ( Ac MNPV) has been investigated as a possible tool for gene therapy, but its inhibition by complement proteins in human serum limits its applicability. Here, we used the baculovirus Bombyx mori nucleopolyhedrovirus ( Bm NPV) to construct a gene delivery vector in which a reporter gene is driven by a cytomegalovirus IE promoter. Enhanced green fluorescent protein (EGFP) and luciferase reporter genes were used to test the efficiency of gene delivery. In vitro complement inactivation data showed that the recombinant Bm NPV vector was more stable in human serum than the recombinant Ac MNPV vector. The recombinant Bm NPV vector successfully delivered the reporter genes into different tissues and organs in mice and chicks. These results demonstrate that the Bm NPV vector is more stability against complement inactivation in human serum than the Ac MNPV vector, and indicate that it may be useful as an effective gene delivery vector for gene therapy in vertebrates.

References

35